azacitidine – Medxy AI

Evaluating Cusatuzumab Combined with Venetoclax ± Azacitidine in Unfit Newly Diagnosed AML: Insights from the Phase Ib ELEVATE Trial

By MedXY 09/09/2026

The phase Ib ELEVATE study demonstrates that cusatuzumab combined with venetoclax and azacitidine offers a promising tolerable and effective frontline therapy for patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy.

Hematology-Oncology news

Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management

By MedXY 09/03/2026

The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.

Hematology-Oncology news

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

By MedXY 07/20/2026

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA registry.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Hematology-Oncology Specialties

ENHANCE-3 Trial: Evaluating Magrolimab Addition to Venetoclax and Azacitidine in Untreated AML Unfit for Intensive Chemotherapy

By MedXY 08/29/2025

The ENHANCE-3 phase 3 trial assessed whether adding magrolimab to venetoclax and azacitidine improves outcomes in untreated AML patients unfit for intensive chemotherapy, finding no survival benefit and a higher rate of fatal adverse events with magrolimab.

Clinical Updates Hematology-Oncology news Specialties

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

By MedXY 08/07/2025

A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.

$Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results$

Clinical Updates Hematology-Oncology news Specialties

Bexmarilimab Plus Azacitidine in High-Risk Myelodysplastic Syndrome and Relapsed/Refractory Acute Myeloid Leukaemia: Phase 1 Dose-Escalation Results

By MedXY 08/02/2025

The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.

Clinical Updates Hematology-Oncology news Specialties

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

By MedXY 07/31/2025

The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.